NDAOPHTHALMICSOLUTION/DROPS
Approved
May 2010
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
9
Data completeness
4/8 — Partial
ZYMAXID (gatifloxacin) by AbbVie is [ see microbiology ( ) ] . Approved for bacterial conjunctivitis, bacterial keratitis. First approved in 2010.
Drug data last refreshed 18h ago
Mechanism of Action
[ see Microbiology ( ) ] .
Indications (2)
Clinical Trials (9)
Besifloxacin Ophthalmic Suspension Verses Gatifloxacin Ophthalmic Solution in Neonates With Bacterial Conjunctivitis
Started May 2011
33 enrolled
Bacterial Conjunctivitis
Concentration of Besifloxacin, Gatifloxacin, and Moxifloxacin in Human Conjunctiva After Topical Instillation
Started Mar 2009
119 enrolled
Healthy
Assessment of the Concentrations of Besifloxacin, Moxifloxacin, or Gatifloxacin in the Aqueous Humor of Subjects
Started Feb 2009
105 enrolled
Cataract Extraction
Non-Inferiority of Gatifloxacin/Prednisolone Association vs Isolated Administration in Prevention of Ocular Infection/Inflammation
Started Jan 2009
101 enrolled
Ocular Infection and Inflammation
A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis
Started Feb 2008
859 enrolled
Bacterial Conjunctivitis
Worked on ZYMAXID at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.